San Diego, CA – According to filings with the U.S. Securities and Exchange Commission, Angiocrine Bioscience is raising $99,372,730.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Paul Finnegan played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Angiocrine Bioscience
Angiocrine Bioscience is a private, clinical stage cell and gene therapy company based in San Diego, California. Angiocrine Bioscience began as a start-up located within Weill Cornell Medical College (New York City) and then relocated to San Diego, one of the leading regenerative biotechnology centers, in 2015. Angiocrine was started by notable and visionary scientists, physicians and entrepreneurs, funded and managed by US-based entrepreneurs. Our company was built on over a decade of research in understanding how the human body naturally repairs and heals itself. Our scientific founders are pioneers in deducing the reparative role endothelial cells and endothelial-derived angiocrine factors which guide the bodys progenitor (stem) cells dispersed throughout various organs. Angiocrine is developing a robust pipeline of Advanced Reparative Medicines. Advanced Reparative Medicines consist of engineered (genetically-modified) human cord endothelial (E-CEL) cells that repair various damaged tissues and organs. Multiple E-CEL products are generated from Angiocrines E-CEL Platform: a proprietary R&D engine that creates multiple clinical product candidates.

To learn more about Angiocrine Bioscience, visit http://angiocrinebioscience.com/

Contact:
Paul Finnegan, Chief Executive Officer
877-784-8496
https://www.linkedin.com/in/pafinnegan/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved